PA
URGN icon

Perceptive Advisors’s UroGen Pharma URGN Stock Holding History

Perceptive Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-199,014
Closed -$7.41M – 152
2017
Q4 		$7.41M Sell
199,014
-70,000
-26% -$2.49M 0.25% 64
2017
Q3 		$8.48M Hold
269,014
– – 0.32% 56
2017
Q2 		$4.86M Buy
+269,014
New +$4.67M 0.24% 67

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Perceptive Advisors's URGN Position: Q1 2018 in Review

Perceptive Advisors sold out of UroGen Pharma (URGN) in Q1 2018, closing a stake of 199,014 shares — an estimated $7.41M sold.

Perceptive Advisors first reported a position in URGN in Q2 2017 and held it in 3 quarters. The position peaked at $8.48M in Q3 2017. 43 funds tracked by Wall St. Rank hold URGN as of Q1 2018.

  • Perceptive Advisors reported no remaining UroGen Pharma position as of Q1 2018 after selling out during the quarter.
  • Perceptive Advisors sold 199,014 UroGen Pharma shares in Q1 2018, an estimated $7.41M.
  • Perceptive Advisors first reported a position in UroGen Pharma in Q2 2017 and held it in 3 quarters.
  • Perceptive Advisors's UroGen Pharma position peaked at $8.48M in Q3 2017.
  • 43 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2018.

Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.